Does epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppress allergic asthma in a murine model?
This study is the first to show the effect of therapeutic EPI with a recombinant form of a hypoallergenic folding variant on the suppression of asthmatic features. Our results suggest that rBet v 1B2 along with its reduced IgE-binding capacity could be a preferred therapeutic allergen than wild-type rBet v 1 in epicutaneous immunotherapy of birch pollen-induced allergic asthma, in particular due to a lower risk of allergic side effect.
The findings of this study indicate that differences in osseointegration between IL and DL implants may be predicted according to differential implant stability.